Project Grant HT94252310604

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the University of Florida to develop a "next-generation" precision adoptive T cell therapy (ACT) approach for the treatment of pediatric high-grade gliomas (HGGs). The $474,656 award, which runs from August 2024 to July 2029, aims to address tumor heterogeneity in pediatric gliomas by using a combination of patient-specific antigen profiling, a novel gene enrichment...

This $231,413 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Massachusetts General Hospital (MGH) to develop in vitro models that recapitulate the development of germ cell neoplasia in situ (GCNIS), the precursor to testicular germ cell tumors. The project aims to produce induced pluripotent stem cell-derived primordial germ cell-like cells and genetically engineer them or human testicular cancer cells to recreate the GCNIS...

This $447,405 Project Grant award was provided by the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393) to The University of Texas Southwestern Medical Center. The 5-year project aims to investigate the role of the developmental transcription factor ONECUT2 in the development of pineoblastoma, a rare childhood cancer that can arise due to mutations in miRNA processing genes DROSHA and DICER1. The research leverages a mouse model...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop and characterize genetically engineered mouse models (GEMMs) that replicate key features of human high-risk rhabdomyosarcoma (RMS). The overarching objectives are to identify therapeutic targets and pathways related to aberrant NOTCH1 activation, which is implicated in 60% of...

This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Seattle Children's Hospital to conduct a Phase 2 clinical trial testing the efficacy of B7-H3 chimeric antigen receptor (CAR) T-cell therapy for children and young adults with diffuse intrinsic pontine glioma (DIPG), a fatal central nervous system tumor. The $456,414 award, effective June 1, 2025 through April 30, 2030, will support the development of advanced neuroimaging...

This Project Grant award of $172,013 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a pediatric oncologist's research efforts to improve outcomes for children with relapsed acute lymphoblastic leukemia (ALL). The principal investigator is leading clinical trials through the Children's Oncology Group (COG) to incorporate novel targeted therapies, such as inotuzumab ozogamicin, into treatment regimens for relapsed and newly diagnosed ALL. The research aims to...

This $540,090 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to characterize the biological basis of epigenetic subtypes in osteosarcoma, a complex bone cancer primarily affecting children and young adults. The overarching goals are to define the core regulatory circuitry driving epigenetic heterogeneity, identify subtype-specific transcription factor vulnerabilities, evaluate intratumoral...

This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will provide $788,589 in funding to Children's Hospital Los Angeles from August 15, 2024 to July 31, 2029. The purpose of the award is to advance understanding of the role of FOXR2 and ETS transcription factors in the development of diffuse midline gliomas, a devastating form of childhood brain cancer. The research will test hypotheses around the requirement of ETS transcription...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research to investigate the origins and treatment vulnerabilities of pediatric treatment-induced gliomas. The $474,337 award to the University of Colorado-Denver will support three key objectives: 1) discovering and validating germline risk factors for radiation-induced...